Vaccine manufacturers Biontech and Pfizer want to apply for approval to administer a third dose of their corona vaccine. According to their own information on Thursday, the two companies plan to submit corresponding data to the US FDA, the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks.
“Although protection against serious illnesses remains high for six months, a decrease in effectiveness against symptomatic cases over time and the occurrence of variants can be expected,” said the two companies. Therefore, a third dose may be required six to twelve months after the first vaccination.
Fight against Delta variant
First data from a study show that a third vaccination with the Biontech vaccine increases the amount of antibodies by five to ten times. According to the information, the companies also expect that a third dose will reliably work against the highly contagious Delta variant of the coronavirus.
The German company Biontech is also currently working on a vaccine that will specifically protect against the Delta variant. The first samples are in production at a plant in Mainz. According to Biontech and its US partner Pfizer, the clinical trials could begin in August. (SDA)